Recent news from the CGRP Forum
Emgality (galcanezumab) receives EU approval in migraine prevention
Emgality (galcanezumab) has become the second anti-CGRP agent to be approved in the EU for the prevention of migraine in adults experiencing at least four migraine days per month. Aimovig (erenumab) received EU approval for the same indication in July 2018.
Read the full report here »
Early response to fremanezumab in high-frequency episodic migraine
Fremanezumab treatment provides rapid migraine prevention and reduces the need for acute medication in patients with high-frequency episodic migraine (HFEM), according to results of a multicentre, double-blind, placebo-controlled phase 2 study (NCT02025556).
Read the full report here »
No link found between medication-overuse headache and CGRP
Patients with medication-overuse headache (MOH) have been shown to have normal serum levels of CGRP and nociceptin, in contrast to previous studies in patients with migraine which showed raised levels of CGRP and low levels of nociceptin.
Read the full report here »
| Becoming a member is easy
Members have free open access simply by registering online. | |